Shattuck Labs (STTK) grants 487,800 stock options to its CMO

Rhea-AI Filing Summary

Shattuck Labs, Inc. reported an insider equity transaction by its Chief Medical Officer, Pandite Arundathy N. On January 10, 2026, she was granted an option to purchase 487,800 shares of common stock at an exercise price of $4.75 per share. The option vests over time: one quarter of the shares on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on her continued service.

On the same date, she disposed of 6,851 shares of common stock at $4.75 per share, and reported owning 199,414 common shares directly after this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pandite Arundathy N.

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/10/2026		F		6,851	D	$4.75	199,414	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock	$4.75	01/10/2026		A		487,800		(1)	01/10/2036	Common Stock	487,800	$0	487,800	D

Explanation of Responses:

1. This option represents a right to purchase a total of 487,800 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer.

	/s/ Andrew R. Neill, Attorney-in-fact for Arundathy N. Pandite	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Shattuck Labs (STTK) report for its CMO?

The Chief Medical Officer, Pandite Arundathy N., reported a grant of stock options and a separate share disposition on January 10, 2026.

How many Shattuck Labs stock options were granted to the CMO?

She received an option to purchase 487,800 shares of Shattuck Labs common stock at an exercise price of $4.75 per share.

What is the vesting schedule for the 487,800 Shattuck Labs options?

One quarter of the option vests on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to continued service.

What common stock transaction did the Shattuck Labs CMO report in Table I?

She reported disposing of 6,851 shares of common stock on January 10, 2026 at a price of $4.75 per share.

How many Shattuck Labs shares does the CMO hold after the Form 4 transactions?

Following the reported non-derivative transaction, she directly beneficially owns 199,414 shares of Shattuck Labs common stock.

Is the reported option grant to the Shattuck Labs CMO a derivative security?

Yes. The filing classifies the grant as a derivative security (a stock option) on common stock, with 487,800 underlying shares.